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Intestinal microbial communities regulate a range of host physiological functions, from energy harvest and
glucose homeostasis to immune development and regulation. Suez et al. (2014) recently demonstrated
that artificial sweeteners alter gut microbial communities, leading to glucose intolerance in both mice and
humans.Microbial communities populate the
mammalian gastrointestinal tract, closely
associating with the host throughout its
life span. The gut is an important site
for metabolic and immune regulation,
and microbial cells here substantially
outnumber human cells in the entire
body, making it a prime location for inter-
action (Human Microbiome Project Con-
sortium, 2012). Microbial communities
are involved in regulation of numerous
host physiological processes, including
metabolism, immunity, and growth (Cox
and Blaser, 2013). Diet is a major driver
of microbial composition and function
within the gut, and distinct microbial pop-
ulations have been associated with both
host adiposity and metabolic diseases
(Cox and Blaser, 2013). Because host
diet, metabolic and immune regulation,
and microbiota are deeply intercon-
nected, disturbance of this homeostasis
can have long-lasting implications for
host development and health (Cox and
Blaser, 2013). Suez et al. (2014) now pro-
vide more evidence of how diet-induced
microbial disturbances alter host health,
demonstrating that dietary sugar alterna-
tives increase glucose intolerance in
mice and human patients.
The last century has seen profound
changes in the way industrialized humans
live, eat, work, and receive medical treat-
ment, impacting the microbial consortia
that live in and on us (Blaser and Falkow,
2009). Modern humans consume diets
that are increasingly high-fat, processed,
and lower in plant matter, differing sub-
stantially from the foods on which our
ancestors subsisted prior to the industrial
revolution. Such changes have affectedboth human physiology and our microbial
inhabitants. In parallel with moderniza-
tion, rates of noncommunicable, ‘‘post-
modern’’ diseases—such as diabetes,
obesity, allergies, and asthma—have
increased alarmingly (Blaser and Falkow,
2009). To combat this trend without
compromising our penchant for sweet
foods, dietary alternatives are frequently
marketed for reducing caloric intake.
The new study by Suez et al. (2014)
described the effects of one such dietary
change—increasing use of noncaloric
artificial sweeteners (NAS)—on host
glucose tolerance. The authors found
that glucose intolerance, a marker of
metabolic diseases such as diabetes
mellitus, was increased in mice by regu-
lar consumption of the sweeteners
saccharin, sucralose, or aspartame (Fig-
ure 1A). These changes accompanied
altered intestinal bacterial communities,
including several organisms that are
associated with obesity, diabetes, and
metabolic disease, and were suppressed
by antibiotic treatment, suggesting a
direct microbial role (Figure 1B).
To test whether changes in microbial
composition induced by NAS consump-
tion led to glucose intolerance, the
authors transferred intestinal microbiota
from NAS-fed or control mice into germ-
free mice, which are maintained under
aseptic conditions, making their gastroin-
testinal tracts completely sterile. Thus,
studies of microbial transfer into germ-
free mice provide a unique opportunity
to test the role of commensal microbiota
on host physiology, since differences be-
tween control and treated animals can be
attributed to the defined microbial inoc-Cell Metabolism 20,ulum given to the germ-free recipients,
rather than to direct effects due to treat-
ment. This approach has been employed
with great success in defining how intesti-
nal microbiota influence host metabolism
under conditions of disturbance, such as
comparing obese versus lean individuals
(Turnbaugh et al., 2006) and during low-
dose antibiotic exposure (Cox et al.,
2014). Suez and colleagues found that
germ-free mice inoculated with micro-
biota from NAS-fed mice became more
glucose intolerant than mice convention-
alized with control microbiota, demon-
strating a causal role of the affected gut
microbial communities (Suez et al., 2014)
(Figure 1C). Similar effects were also
seen in germ-free mice receiving control
microbiota that had been grown in vitro
in the presence of NAS (Figure 1D). These
results indicate that NAS consumption
directly altered microbial composition
and metabolism, leading to the important
downstream metabolic effects.
In each of these experiments, similar
impacts were seen on microbial gene
composition, as assessed by shotgun
metagenomic sequencing, indicating
that NAS exerted an impact on microbial
function. Glycan degradation pathways
were strongly affected, leading to in-
creased short-chain fatty acid (SCFA)
abundance. Among other properties,
SCFAs are consumed by intestinal epithe-
lial cells, leading to enhanced energy har-
vest by the host (Turnbaugh et al., 2006),
providing one possible mechanism for
microbial alterations of glucose tolerance
induced by NAS consumption. However,
intestinal SCFA production also has





Figure 1. Noncaloric Artificial Sweeteners (NAS) Induce Glucose Intolerance via Microbial Dysbiosis
(A–E) Schematic of the experimental design (Suez et al., 2014). NAS induction (A): Mice fed NAS developed altered intestinal microbial communities and glucose
intolerance. Antibiotic suppression (B): treating these mice with antibiotics countered this effect, indicating microbial involvement. Microbial transfer (C) from
NAS-fed mice to germ-free (GF) mice fed normal chow induced glucose intolerance, compared to GF mice receiving control microbiota. NAS directly affects
microbiota (D): Microbiota from control mice were grown in the presence of NAS in vitro and transferred to GF mice, inducing glucose intolerance compared
to microbiota cultured without NAS. Personalized human response depends on microbiota (E): The responsiveness of adult human patients to NAS-induced
glucose intolerance depended on prior microbial composition. When transferred to GF mice, microbiota from NAS-responsive patients induced glucose
intolerance, while microbiota from NAS-non-responsive patients did not.
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peptide (GLP)-1 and improved glucose
tolerance (Tolhurst et al., 2012; Yadav
et al., 2013), so the mechanisms of NAS-
induced, microbial-mediated alterations
in glucose tolerance are unclear and likely
more complex than SCFAs alone.
The authors discovered a similar
response to NAS consumption in nondia-
betic humans, showing that these effects
extend to human dietary choices. Healthy
volunteers who did not normally consume
NAS were fed saccharin daily for 1 week.
The majority of these subjects developed702 Cell Metabolism 20, November 4, 2014 ªpoorer glycemic responses within 1 week,
and had altered intestinal microbiota, dis-
tinguishing them from nonresponders,
who had neither altered glycemic re-
sponses nor microbial changes. Germ-
free mice conventionalized with stool
samples fromNAS responders developed
glucose intolerance compared to mice
conventionalized with stools from the
same patients pre-NAS or from nonre-
sponders (Figure 1E). These findings
again provide evidence that NAS-induced
dysbiosis had a causal role in inducing
the glucose intolerance seen in these pa-2014 Elsevier Inc.tients. These findings were consistent
with the authors’ observations from a
larger cohort of humans, in whom regular
NAS consumption was positively corre-
lated with intestinal microbial changes
and multiple clinical parameters, includ-
ing glucose intolerance and weight (Suez
et al., 2014).
While specific microbial compositions
clearly predispose human patients to
NAS-induced metabolic effects, the fac-
tors that contribute to this susceptibility
are unclear and warrant further investiga-
tion. Host genetics, diet, immune status,
Cell Metabolism
Previewsunderlying diseases, and medical treat-
ments all are features of patient history
that influence human microbial composi-
tion and could determine individual re-
sponses to NAS consumption. We do
not know whether NAS select against
certain microbes by inhibiting their func-
tion, allowing their unaffected competi-
tors to flourish, or whether they are
direct stimulants of other organisms, or
both. The mode of selection remains to
be determined, but the problem is trac-
table. Also unclear is whether metabolic
effects relate to differences in food
and liquid intake between experimental
groups. Future studies should carefully
control intakes to minimize potential
cofounder effects.
Biological variation similarly defines
patient susceptibility to other microbe-
mediated treatments, such as drug
metabolism (Maurice et al., 2013) and
dietary responses (Salonen et al.,
2014). These studies all highlight the
need to establish how microbial varia-tion influences host responses to diet,
therapies, and disease. The develop-
ment and implementation of personal-
ized treatments for complex diseases
could likely involve manipulation of the
microbiota.
In the interim, the findings of Suez and
colleagues have more immediate conse-
quences: that dietary sugar alternatives
meant to stave off the risk of obesity and
diabetes may actually increase disease
risk due to microbial alterations (Suez
et al., 2014). Other dietary additives may
provoke similar microbial changes and
deserve further investigation. This is yet
another indication that we are not alone
and that microbial disturbances can lead
to unexpected physiological effects.REFERENCES
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A substantive literature has accumulated implicating sphingolipids, in particular ceramides, as mediators
of insulin resistance in metabolic syndrome. Thanks to recent technical advances in mouse genetics and lip-
idomics, two independent laboratories identify the same sphingolipid, C16:0-ceramide, as principal mediator
of obesity-related insulin resistance (Turpin et al., 2014; Raichur et al., 2014).The term ‘‘metabolic syndrome’’ defines
a constellation of distinct clinical entities
that present together in aging populations
of wealthy and newly developed nations.
Insulin resistance, obesity, hyperlipid-
emia, and hypertension represent core
abnormalities of metabolic syndrome.
This syndrome accelerates progression
of major diseases such as atherosclerotic
vascular disease and type 2 diabetes,
leading to increased morbidity and mor-
tality. Refinement of criteria to improveour understanding of progression of these
comorbid conditions is an active area of
ongoing investigation (Eckel et al., 2010).
Much evidence supports altered sphin-
golipid metabolism and, more specif-
ically, enhanced ceramide generation as
integral to progression of type 2 diabetes
and insulin resistance, contributing to
metabolic syndrome (Chavez and Sum-
mers, 2012). In addition to ceramide,
glycosphingolipid metabolism may be
deregulated in type 2 diabetes (Hla andDannenberg, 2012). Thus, molecular
description of specific sphingolipid spe-
cies-mediating disease pathophysiology
is critical. As estimates of the number of
bioactive sphingolipid mediators range
from 4,000 to 60,000 (Merrill, 2011), this
is indeed a daunting challenge. Now,
two Cell Metabolism articles conclude
that a specific ceramide species, C16:0-
ceramide, mediates the key pathophysi-
ology of insulin resistance (Turpin et al.,
2014; Raichur et al., 2014).November 4, 2014 ª2014 Elsevier Inc. 703
